Completed OBSERVATIONAL NCT01095081

GARDIAN, Gadovist in Routine Diagnostic Magnetic Resonance Imaging Administration in Non-selected Patients (GARDIAN)

Sponsor: Bayer

Conditions Magnetic Resonance Angiography Magnetic Resonance Imaging

Interventions Gadobutrol (Gadovist, BAY86-4875)

Updated 10 times since 2017 Last updated: Jan 19, 2015 Started: Jul 31, 2010 Primary completion: Apr 30, 2013 Completion: Apr 30, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Magnetic Resonance Angiography and Magnetic Resonance Imaging and is currently completed. Bayer leads this study, which shows 10 recorded versions since 2010 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

10 versions recorded

Sep 2025 — Present [monthly]

Completed
Sep 2024 — Sep 2025 [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Feb 2020 — Jan 2021 [monthly]

Completed

▶ Show 5 earlier versions

Jun 2018 — Feb 2020 [monthly]

Completed
May 2018 — Jun 2018 [monthly]

Completed
Apr 2018 — May 2018 [monthly]

Completed

Phase: NA → None
Aug 2017 — Apr 2018 [monthly]

Completed NA
Jan 2017 — Aug 2017 [monthly]

Completed NA

First recorded

Jul 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bayer

Data source: Bayer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Many Locations, Bosnia and Herzegovina , Many Locations, Canada , Many Locations, China , Many Locations, Czechia , Many Locations, France , Many Locations, Germany , Many Locations, Greece , Many Locations, Hong Kong , Many Locations, Hungary , Many Locations, Italy and 10 more locations